Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) EBITDA (2016 - 2025)

Agios Pharmaceuticals' EBITDA history spans 14 years, with the latest figure at -$121.6 million for Q4 2025.

  • For Q4 2025, EBITDA rose 2.77% year-over-year to -$121.6 million; the TTM value through Dec 2025 reached -$472.1 million, down 10.9%, while the annual FY2025 figure was -$472.1 million, 10.9% down from the prior year.
  • EBITDA reached -$121.6 million in Q4 2025 per AGIO's latest filing, down from -$116.9 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $1.9 billion in Q1 2021 to a low of -$127.1 million in Q2 2025.
  • Average EBITDA over 5 years is -$4.2 million, with a median of -$101.0 million recorded in 2022.
  • Peak YoY movement for EBITDA: soared 4740.99% in 2021, then crashed 105.4% in 2022.
  • A 5-year view of EBITDA shows it stood at -$104.8 million in 2021, then grew by 5.39% to -$99.2 million in 2022, then fell by 7.16% to -$106.3 million in 2023, then decreased by 17.65% to -$125.0 million in 2024, then grew by 2.77% to -$121.6 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's EBITDA are -$121.6 million (Q4 2025), -$116.9 million (Q3 2025), and -$127.1 million (Q2 2025).